Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study

Authors


  • Disclosures No commercial or other interests or associations exist, on the part of myself and of my co-authors, that might be perceived as posing a conflict of interest or bias in connection with the submitted article.
    The authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and the accuracy of the data analysis. The authors also have no direct or indirect commercial financial incentive associated with publishing this study.

Byung Ha Chung, Department of Urology, Yonsei University Health System, Gangnam Severance Hospital P.O. Box 1217, Seoul, Korea
Tel.: + 82 2 2019 3474
Fax: + 82 2 3462 8887
Email: chung646@yuhs.ac

Summary

Aims:  To compare the rapidity of improvement in lower urinary tract symptoms (LUTS) for the doxazosin gastrointestinal therapeutic system (GITS) and tamsulosin in benign prostatic hyperplasia (BPH) patients.

Methods:  A total of 207 patients were randomised to one of two groups for a 12-week daily treatment with doxazosin-GITS 4 mg or tamsulosin 0.2 mg. The primary end-point was to compare the early onsets of efficacy between the two drugs. This was assessed by analysing the changes from baseline in the total International Prostate Symptom Score (IPSS) in the early period of treatment. Secondary aims were to compare improvements in obstructive/irritative subscore and quality of life (QoL) score between the two groups, and to evaluate the adverse events (AEs) with the drugs.

Results:  After 12 weeks of treatment, both groups showed significant improvements in IPSS scores (total, obstructive and irritative subscores, QoL score) from baseline (p < 0.0001). However, the doxazosin-GITS group showed significantly greater improvements in total IPSS and obstructive subscore than the tamsulosin group in the early period (p < 0.05). Improvements in irritative subscore (within 4 weeks) and QoL score (during 12 weeks) were not significantly different between the groups. The incidences of AEs were similar between the groups.

Conclusion:  In this study, doxazosin-GITS showed significantly more rapid onset of efficacy and similar AEs compared with tamsulosin in BPH patients with LUTS. We believe this will probably improve patient compliance. Future studies with a larger number of patients and a longer follow-up period will be required to confirm this.

Ancillary